Schrödinger

Schrödinger

Computational platform for drug discovery

Overview

Schrödinger provides a computational platform for drug discovery used by biopharmaceutical companies, academic institutions, and government laboratories around the world. The core offering is an integrated software suite for molecular modeling, simulations, and analytics, which clients access through software licensing or collaborative research agreements, and may also participate in wholly-owned or collaborative drug-discovery programs. The company differentiates itself with a long history since 1990 and a global footprint, combining a full end-to-end platform with direct drug-discovery partnerships and extensive services. Its goal is to advance science and talent by strengthening its platform and helping partners discover and develop new medicines using computational methods and collaborative programs.

Significant Headcount Growth

About Schrödinger

Simplify's Rating
Why Schrödinger is rated
B+
Rated A on Competitive Edge
Rated A on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

1990

Get referred to Schrödinger

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $58.9 million, beating estimates and validating demand momentum.
  • Schrödinger raised 2026 drug-discovery revenue guidance to $65 million-$75 million on August 6 2026.
  • Simcere signed July 10 2026, expanding milestone and royalty optionality across global development programs.

What critics are saying

  • May 18 2026 CCO Mannix Aklian exited, signaling sales execution risk during the hosted transition.
  • Software gross margin fell to 69% in Q1 2026, squeezing profitability as hosted revenue grows.
  • If Bunsen misses adoption by end-2026, software growth stalls and Schrödinger becomes a drug-discovery laggard.

What makes Schrödinger unique

  • Physics-based platform still wins at BMS, Lilly, and Simcere in 2026.
  • Bunsen, launched July 27 2026, turns Schrödinger workflows into an AI co-scientist.
  • Hosted software shifted to 47% of revenue in Q2 2026, deepening customer lock-in.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$951.4M

Above

Industry Average

Funded Over

11 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Paid Vacation

Parental Leave

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

6%
Yahoo Finance
Aug 5th, 2026
Bristol Myers Squibb deploys Schrödinger's AI co-scientist Bunsen for drug discovery

Schrödinger has announced a strategic collaboration with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organisation. The agreement expands upon their existing partnership, enabling BMS scientists to explore more scientific possibilities and accelerate discovery decisions. Under the collaboration, Schrödinger will work with BMS scientists to develop novel functionality within Bunsen alongside its computational technologies and RetroSynth AI-driven synthesis planning platform. Unlike general-purpose agents, Bunsen is optimised to execute Schrödinger's physics-based computational platform by planning and running complex molecular discovery workflows. The deployment allows BMS to scale its predict-first computational approach across a broader group of scientists, helping them navigate molecular design space more efficiently in discovering innovative medicines.

Associated Press
Jul 27th, 2026
Schrödinger launches Bunsen, an AI co-scientist for molecular discovery

Schrödinger has launched Bunsen, an agentic AI co-scientist designed to accelerate molecular discovery. Unlike general-purpose AI systems, Bunsen executes Schrödinger's validated computational methods and leverages the company's physics-based molecular discovery expertise. The platform helps researchers understand scientific objectives, develop computational strategies, execute molecular discovery workflows and interpret results. This enables computational chemists to run concurrent research sessions whilst making advanced methods accessible to drug hunters without computational chemistry backgrounds. Schrödinger is collaborating with NVIDIA and Google Cloud to provide a co-engineered AI platform for early Bunsen customers. The integration includes Google Cloud's elastic computing infrastructure and NVIDIA BioNeMo Agent Toolkit with RTX PRO 6000 Blackwell Server Edition GPUs. The early access version is now available to select customers, with full commercial release expected by the end of 2026.

Endpoints News
Jul 27th, 2026
Exclusive: Schrödinger CEO 'couldn't be more pleased to be wrong' in launch of AI agent Bunsen.

Exclusive: Schrödinger CEO 'couldn't be more pleased to be wrong' in launch of AI agent Bunsen. Senior biopharma correspondent. Three years ago, Schrödinger CEO Ramy Farid ruffled some feathers by pushing back on the AI fever of the moment. He said... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Simcere Pharmaceutical Group
Jul 10th, 2026
Simcere and Schrödinger enter global drug discovery and development collaboration.

Simcere and Schrödinger enter global drug discovery and development collaboration. Release time:2026-07-10 July 10, 2026 - Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into a global drug discovery and development collaboration with Schrödinger, Inc. to advance an innovative program based on unmet clinical needs and Simcere's therapeutic area expertise. Zhou Gaobo, Chief Investment Officer of Simcere said: "We are delighted to establish a strategic collaboration with Schrödinger, a global leader in computational drug discovery. This partnership deeply integrates Schrödinger's world-leading computational platform and drug design expertise with Simcere's efficient research and development and commercialization platform. We look forward to leveraging our complementary strengths and collaborative innovation to accelerate the discovery, development and commercialization of cutting-edge therapies and bring more effective treatment options to patients worldwide." Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships of Schrödinger commented: "We are pleased to initiate this strategic collaboration with Simcere to jointly discover and develop innovative medicines to address significant unmet clinical needs. This agreement builds on our successful model of discovering innovative clinical candidates for high-value targets. By combining our track record in predict-first differentiated drug design with Simcere's excellent reputation for innovative R&D and clinical development execution globally, we aim to accelerate the discovery and development of therapies for patients around the world." Schrödinger, leveraging its industry-leading physics-based platform and expertise, will lead computational drug design and optimization for the joint research collaboration. Simcere will lead subsequent preclinical and clinical development following completion of the joint discovery phase. Schrödinger is eligible to receive discovery, development and commercial milestones for all programs in the collaboration, as well as tiered royalties on net sales. About Simcere Simcere Pharmaceutical Group Limited(2096.HK)is a pharmaceutical company driven by innovation and focusing on four therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. Simcere Pharmaceutical Group proactively explore areas with significant unmet needs, and its mission is 'For patients, for life'. Driven by its in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many innovative companies and research institutes. Learn more atwww.simcere.com. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow Simcere Pharmaceutical Group on LinkedIn, or visit its blog, Extrapolations.com.

Yahoo Finance
Jun 21st, 2026
Schrödinger's 2026 ACV outlook shows 10-15% growth to $228M as drug discovery revenue doubles

Schrodinger Inc, a software provider for drug discovery and material science, reported 12% year-on-year growth in annual contract value to $28.4 million in Q1 2026. The company is transitioning to a hosted software licensing model, which caused software revenue to decline 21%, whilst drug discovery revenue more than doubled to $22.9 million. For full-year 2026, Schrodinger expects annual contract value between $218 million and $228 million, representing 10% to 15% growth, with drug discovery revenue projected at $55 million to $65 million. The company anticipates Q2 2026 annual contract value of $19 million to $23 million. Schrodinger shares have risen approximately 13% over the past month and are backed by 31 hedge funds, including the Bill & Melinda Gates Foundation Trust.

Recently Posted Jobs

Sign up to get curated job recommendations

Schrödinger is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →